Reimbursed & Ready: Winning in the Australian MedTech Market
AusBiotech Health Technology Assessment (HTA) Workshop
The AusBiotech Health Technology Assessment (HTA) Workshop “Reimbursed & Ready: Winning in the Australian MedTech Market” will provide a comprehensive overview of Australia’s healthcare reimbursement process in Australia, with a focus on the MedTech industry. Presented by George Papadopoulos and Blaise Agresta from Lucid Health Consulting.
Reimbursement is a critical factor in the adoption and success of medical technologies, as Australia operates a centralised system for healthcare funding. This workshop will cover key reimbursement pathways, including:
The Medicare Benefits Schedule (MBS) for medical services
The Pharmaceutical Benefits Scheme (PBS) for medicines
The Prescribed List of Medical Devices and Human Tissue Products (PL), for medical devices and human tissue products for which private health insurers must pay benefits
Participants will gain insights into the key decision-making bodies that govern reimbursement approvals, including the Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC), and Medical Devices and Human Tissue Advisory Committee (MDHTAC).
The workshop will outline the importance of HTA, focusing on value-for-money, comparative evidence, economic evaluations and financial forecasting in reimbursement applications. Additionally, the session will highlight the importance of early planning, strong clinical evidence, and strategic positioning for MedTech organisations aiming to secure reimbursement in the Australian market.
Workshop Details
Date:
6 May 2025
Location:
ICC Sydney
Time:
8:30 AM – 1:30 PM
Pricing
Workshop
$220 inc. GST
AusBiotech Member
Workshop
$275 inc. GST
Non-Member
Workshop Agenda
8:30 AM – 9:00 AM | Registration
9:00 AM – 10:15 AM | Session 1
10:15 AM – 10:30 AM | Morning Tea Break
10:30 AM – 12:30 PM | Sessions 2 & 3
12:30 PM – 1:30 PM | Lunch, Debrief, and Q&A
Workshop Facilitator
George Papadopoulos, Partner and Director at Lucid Health Consulting
George is a healthcare pricing and reimbursement professional with over 30 years’ experience across in local and international healthcare companies. George worked in both local operating company and global levels in increasing levels of responsibility for leading pharmaceutical companies in Australia, Belgium and the United States. He has previously worked for Pharmacia, Johnson and Johnson, Schering-Plough and Merck. George has experience in the pharmaceutical, biotech and medical device industry, including clinical research, health economics, reimbursement, pricing and business development.
George is currently a Partner and Director at Lucid Health Consulting, a strategic healthcare consultancy specialising in optimising market entry for pharmaceuticals, biotech products, medical devices and technologies across Australia and the Asia-Pacific region. These services include health economics strategy, health technology assessment, pricing and reimbursement strategy development and advisory board participation; ensuring clients achieve successful market access and sustainable growth.
George received his BSc (Hons) from the University of Sydney and Grad Dip Epi (Pharmacoepi) from University of Newcastle. He is Past-President of the Board of ARCS; Member of Heath Economics Expert Panel of Ausbiotech and a member of HTAi (Health Technology Association International), iHEA (International Health Economics Association), ISPOR and ISPOR Australian Chapter and of the AICD (Australian Institute of Company Directors).
Blaise Agresta, Reimbursement and HTA Lead, Lucid Health Consulting
Blaise Agresta is a distinguished leader with nearly two decades of experience in health economics, financial modelling, and market access across the industry, consulting, and academic sectors. With expertise in strategic development, economic modelling, and health technology assessment (HTA), he has played a pivotal role in shaping reimbursement strategies for pharmaceutical and medical technology companies. As the Managing Director of MAOSS and an HTA and Reimbursement Lead at Lucid Healthcare Consulting, he has advised on PBAC submissions, developed innovative pricing strategies, and conducted complex statistical analyses. His previous roles at the University of Sydney and Janssen Pharmaceuticals further highlight his ability to drive policy changes, enhance financial impact analyses, and manage high-stakes healthcare projects.
Blaise holds multiple advanced degrees, including a Master of Business Administration, a Master of Applied Finance, and a Master of Public Health. His career achievements include securing successful PBAC recommendations for major pharmaceutical products, leading MSAC evaluations, and contributing to numerous academic publications on health economics and policy. An adept data scientist and strategic thinker, he has successfully bridged the gap between clinical research, economic decision-making, and strategic brand management making significant contributions to healthcare access and policy development in Australia and internationally.
The Health Technology Assessment (HTA) Workshop “Reimbursed & Ready: Winning in the Australian MedTech Market” is proudly sponsored by Lucid Health Consulting.